Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Stoke Therapeutics, Inc.

< Previous 1 2 3 Next >
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces CEO Transition
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.